Posted on

The world’s biggest psychedelic therapy provider

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Field Trip Health (FTRP) just got one step closer to reaching its goal of running 75 psychedelic therapy clinics by 2024.

The company opened three new treatment centers in Seattle, Vancouver and Fredericton. It now administers ketamine-assisted therapy at eight clinics across North America and one in Amsterdam.

The treatment is proving to be effective with clients’ depression scores dropping from an average of 17 (severe) to 6 (mild) and benefits lasting at least 120 days.

PDF of article

Posted on

Measuring brain penetration?

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Mindset Pharma (MSET) is rapidly expanding its pipeline thanks to advancements made by its Co-operative Psychedelics Evaluation (COPE) program, which aims to develop preclinical benchmark data for psychedelic medicines.

Researchers established standard pharmacokinetic, brain penetration, and drug discrimination data and protocols for psilocybin, LSD, and 5-MeO-DMT. The company also developed procedures to determine concentrations of the drugs in plasma, brain, and cerebral spinal fluid.

These finding, which were gathered in collaboration with InterVivo Solutions, will help drug developers understand how compounds interact with the body. Mindset will commercialize the data by making it available to other InterVivo clients.

PDF of article

Posted on

New advisor supports expansion into psychedelic treatments

BLACKHAWK GROWTH APPOINTS NEW ADVISOR TO SUPPORT EXPANSION INTO PSYCHEDELICS AND MENTAL HEALTH TREATMENTS

Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is accelerating its expansion into psychedelic and mental health treatments with a new addition to its team.

Yesterday, Blackhawk appointed Dr. Lahiru Russell, the founder and chief scientist of Digital Health Technologies, as the company’s medical advisor. Using her 10+ years of experience in clinical trials and psycho-oncology research, Dr. Russel is developing a mindfulness-based intervention platform that will help patients regulate their emotions and thoughts to reduce negative mental health conditions.

Blackhawk’s subsidiary, MindBio Therapeutics, will be able to utilize Dr. Russel’s IP in its microdosing research through a commercialization agreement with Digital Mind Technology, which was established last month.

MindBio will also utilize Google Cloud’s “Health Care Solutions” to recruit, enroll, and engage with patients in its internal clinical trials and to accelerate drug development.

PDF of article

Posted on

Is MDMA the Viagra for women?

LOVE PHARMA INC., ANNOUNCES LISTING ON FRANKFURT STOCK EXCHANGE

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line.

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mindcure (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

PDF of article 1

PDF of article 2

Posted on

Never leave home without your inhaler ;)

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

Cybin Inc. (CYBN) developed a new device that delivers psychedelic medicine through inhalation.

Inhaling psychedelics could be superior to oral administration, as it could result in optimized session timing, lower doses, and greater control for healthcare providers.

The company filed an international patent application for the method and the device, which has potential to gain coverage in 153 countries.

PDF of article

Posted on

Managing pain across the globe

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS BRINGS DIGITAL MENTAL HEALTH TECHNOLOGY TO PSYCHEDELICS CLINICAL TRIALS

Could microdosing + this new technology reduce pain in cancer patients?

MindBio Therapeutics is developing a technology platform to integrate with psychedelic therapy to prevent the mental health of cancer patients from deteriorating.

By utilizing wearable devices, the platform is designed to help with pain management to prevent depression, existential distress and anxiety.

MindBio Therapeutics will use the mindfulness app in an upcoming  Phase 2 microdosing trial, which is funded by the New Zealand government, to see if it provides additional benefits to late-stage cancer patients compared to microdosing alone.

The company aims to commercialize the application globally and believes the tech has potential to receive government funding in Europe.

PDF of article

Posted on

More psilocybin please!

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

This new extraction method could yield more psilocybin from a single mushroom than previously possible.

Natural psilocybin extraction can have low and unstable yields, which is why many companies opt for synthetic versions. When mushrooms are dehydrated, the total psilocybin/psilocin content extracted  is three times lower than the total amount believed to be in the mushroom.

Optimi Health (OPTI) developed an extraction technique that not only increases the yield of natural psilocybin, but also protects the compounds from degeneration while reducing the cost of the final drug. On Tuesday, the company announced that it filed a provisional patent application to protect the process.

PDF of article

Posted on

New ways to consume drugs!

Cannabis Global Launches Research Program for Psychedelics Infusions for Foods and Beverages

Will shroom edibles and drinks be the next big thing in Cali?

Cannabis Global Inc. (CBGL) is developing methods to infuse psilocybin and psilocin, as well as other compounds found in psychedelic mushrooms, into foods and beverages.

The LA-based company has initiated research into infusion methods to improve bioavailability of the compounds and to mask the bitter flavour of the mushrooms. The company has already filed 9 patent applications for its cannabinoid infusion technologies including polymeric nanoparticle and emulsion infusions, which it hopes to leverage for this new research program.

With the state of California on track to have a psilocybin legalization measure on the 2022 ballot, the program could potentially serve a large marketplace in the near future.

PDF of article

Posted on

This cannabis extraction company could take over the psilocybin market

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

These two companies are joining forces to become a leader in commercialized psilocybin extracts.

Pure Extracts (PULL), a cannabis, hemp, and mushroom extraction company, signed a Joint Venture agreement with Psyence Group (PSYG) to form “Pure Psyence”.

The agreement leverages Psyence Group’s licensed cultivation facility and standardized psilocybin mushroom supply to create high-purity, naturally-derived mushroom extracts.

The combined expertise will make standardized psilocybin more accessible to Canadian research institutions and will allow Pure Psyence to conduct human clinical trials using the extracts.

PDF of article

Posted on

Let me hit that vape

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

Will psychedelic therapy soon involve vaping shrooms?

Delic Holdings Corp. (DELC) is the first company to receive Health Canada approval to research psilocybin vaporization.

On Monday, Delic entered into an agreement to acquire Ketamine Wellness Clinics, a company that runs 10 ketamine infusion centers across 8 states. The deal increases Delic’s total number of clinics to 12 and adds over 60 medical professionals to the team, making it the largest psychedelic wellness chain in the US. Within the next 18 months, the company hopes to grow this number to 27 clinics!

Once granted FDA-approval, DELIC aims to offer other psychedelic treatments at these locations including MDMA and psilocybin therapy, which could potentially use the vaporization technology!

PDF of article